2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Quality Improvement, Diseases, Immunology, Autoimmune Disorders, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Animal Model
PAPER

4126 A drug-controllable lentivirus based-in vivo CD19/BCMA dual targeting CAR-T platform for severe autoimmune diseases

xiaoling wang, xiaobin song2, Huan Wang3, nian chen4, xiaofeng jia5, yuqing lin6, lihong shen7, Ming Jin8, jiajia wu9, Yingyong Xu, MD, PhD, MBA10, Jiapan Hu11, yixuan zhou12, Heng Mei, MD, PhD13, Yanan Yue14, Luhan Yang, PhD15
1 Qihan Biotechnology, Hangzhou, China
2 Qihan Biotechnology, Hangzhou, China
3 Qihan Biotechnology, Hangzhou, China
4 Qihan Biotechnology, Hangzhou, China
5 Qihan Biotechnology, Hangzhou, China
6 Qihan Biotechnology, Hangzhou, China
7 Qihan Biotechnology, Hangzhou, China
8 Qihan Biotechnology, Hangzhou, China
9 Qihan Biotechnology, Hangzhou, China
10 Qihan Biotechnology, Hangzhou, China
11 Qihan Biotechnology, Hangzhou, China
12 Qihan Biotechnology, Hangzhou, China
13 Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, wuhan, China
14 Qihan Biotechnology, Hangzhou, China
15 Qihan Biotechnology, Hangzhou, China

Background: Autologous CD19-directed CAR-T cell therapy has demonstrated promising clinical efficacy in autoimmune diseases (AIDs), particularly systemic lupus erythematosus (SLE), by depleting pathogenic B-cell populations and re-establishing immune homeostasis. However, its widespread application is limited by individualized manufacturing, lengthy and costly ex vivo cell production, and the need for lymphodepleting chemotherapy before infusion.

To address these challenges, we aimed to develop QI-019C, a safe and effective in vivo lentiviral gene delivery platform encoding a dual-targeting CD19/BCMA CAR capable of generating functional CAR-T cells directly in vivo. Simultaneous targeting of CD19 and BCMA was designed to achieve broader depletion of pathogenic B-cell populations and plasma cells. To improve the safety profile for autoimmune indications, a truncated epidermal growth factor receptor (tEGFR) safety switch was incorporated to enable rapid antibody-mediated elimination of CAR-T cells when clinically indicated.

Methods: The functionality of the tEGFR safety switch was evaluated using an in vitro antibody-dependent cellular cytotoxicity (ADCC) assay by co-culturing tEGFR-expressing CAR-T cells with cetuximab and peripheral blood-derived natural killer (PBNK) cells. CAR specificity, transduction efficiency, and serial cytotoxic activity were assessed using conventionally manufactured CAR-T cells generated ex vivo. The in vivo transduction efficiency, antitumor activity, and preliminary safety of QI-019C were further evaluated in human PBMC-engrafted humanized mouse models bearing CD19- or BCMA-positive tumors following systemic administration of the lentiviral vector?

Results:

QI-019C achieved robust generation of CD19/BCMA dual-targeting CAR-T cells, with >95% of CAR-positive cells co-expressing the tEGFR safety switch. In ADCC assays, cetuximab in combination with peripheral blood NK (PBNK) cells eliminated >95% of CAR-T cells within 24 hours, demonstrating effective safety-switch activation. Ex vivo-generated QI-019C CAR-T cells exhibited selective transduction, potent antigen-specific cytotoxicity, and sustained serial killing against both CD19- and BCMA-expressing target cells. In PBMC-humanized mouse models, systemic administration of QI-019C enabled in vivo generation of functional CAR-T cells, producing >95% tumor reduction in both CD19- and BCMA-positive tumor models without unexpected safety findings.

Conclusions: These nonclinical findings demonstrate that QI-019C enables robust in vivo generation of functional CD19/BCMA dual-targeting CAR-T cells capable of eliminating both CD19- and BCMA-positive target cells. The incorporated tEGFR safety switch allows rapid antibody-mediated depletion of CAR-T cells, providing an important safety control mechanism for in vivo CAR-T therapy. Together, these results establish proof-of-concept for a drug-controllable in vivo CAR-T platform and support further clinical development of QI-019C for the treatment of autoimmune diseases.
Luhan Yang, PhD: No relevant conflicts of interest to declare.